Skip to main content
main-content

The independent medical news service

Prostate cancer

14-06-2019 | Oncology | News | Article

ENZAMET supports enzalutamide use in men with metastatic CSPC

Men with metastatic castration-sensitive prostate cancer derive a significant overall survival benefit from the addition of enzalutamide to standard testosterone suppression, show phase III trial results.

04-06-2019 | Oncology | Main feed | News

Metformin addition ruled out for nondiabetic men with metastatic CRPC

The outcomes of nondiabetic men with metastatic castration-resistant prostate cancer are not improved with the addition of metformin to docetaxel, finds the French TAXOMET trial.

03-06-2019 | Oncology | News | Article

Olaparib response may depend on DDR mutation type in mCRPC

The degree of response to olaparib among patients with heavily pretreated metastatic castration-resistant prostate cancer varies according to the type of DNA damage repair alteration the tumor carries, research shows.

02-06-2019 | Oncology | News | Article

TITAN: OS benefit seen with apalutamide in metastatic CSPC setting

Supplementing androgen deprivation therapy with apalutamide leads to significant improvements in survival outcomes in men with metastatic castration-sensitive prostate cancer, show phase III trial results.

01-06-2019 | Oncology | News | Article

ARAMIS QoL results add support for darolutamide in nonmetastatic CRPC

Men with nonmetastatic castration-resistant prostate cancer enrolled in the ARAMIS trial report favorable quality of life outcomes with darolutamide relative to placebo.

28-05-2019 | Oncology | News | Article

Socioeconomic factors major players in prostate cancer racial disparity

Research published in JAMA Oncology confirms that prostate cancer-specific mortality is not significantly different between Black and White men with nonmetastatic disease when access to care and treatment is comparable.

20-05-2019 | Oncology | News | Article

Poor glycemic control linked to prostate cancer progression

In men with prostate cancer and diabetes, higher glycated hemoglobin levels are associated with an increased risk for developing metastases and castration-resistant disease, findings indicate.

09-05-2019 | Oncology | News | Article

5α-reductase inhibitors linked to elevated prostate cancer death rates

Use of 5α-reductase inhibitors, typically for benign prostatic hyperplasia, may delay prostate cancer diagnosis and thus increase mortality risk, show results of a large population-based cohort study.

03-05-2019 | Oncology | News | Article

Biosimilar pegfilgrastim receives EMA go-ahead, generic cabazitaxel does not

Read more on these announcements here

02-05-2019 | Prostate cancer | News | Article

Single HDR brachytherapy treatment effective for low-risk prostate cancer

A single dose of high-dose rate brachytherapy prevents biochemical recurrence for at least 3 years in patients with low-risk prostate cancer, but is less effective among those with higher-risk disease, researchers report.

02-05-2019 | Oncology | News | Article

Biologic, genetic markers predict radiation toxicity in oncology patients

A combination of biologic and genetic markers may be useful to predict which patients will experience toxicity following radiotherapy, suggest data presented at the ESTRO 38 conference in Milan, Italy.

25-04-2019 | Oncology | News | Article

LATITUDE final analysis confirms abiraterone benefit for mCSPC

Adding abiraterone acetate plus prednisone to androgen deprivation therapy continues to provide an overall survival advantage in the first-line treatment of men with high-risk metastatic castration-sensitive prostate cancer, report the LATITUDE investigators.

23-04-2019 | Oncology | News | Article

SABR may improve survival in oligometastatic cancer

The phase II SABR-COMET study has indicated that stereotactic ablative radiotherapy prolongs overall and progression-free survival versus palliative treatment in patients with up to five oligometastases.

18-04-2019 | Diabetes | News | Article

Study bolsters evidence for 5 alpha-reductase inhibitor link to type 2 diabetes

Men with benign prostatic hyperplasia undergoing long-term treatment with 5α-reductase inhibitors are significantly more likely to develop type 2 diabetes than those receiving the α-blocker tamsulosin, population-based study data show.

18-04-2019 | Oncology | News | Article

68Ga-PSMA-11 PET shows ‘high accuracy’ for localizing recurrent prostate cancer

Positron emission tomography using 68gallium-labeled ligands of the prostate-specific membrane antigen is accurate, reproducible, and safe in localizing biochemically recurrent prostate cancer, according to the results of a prospective trial.

11-04-2019 | Oncology | News | Article

Prostate cancer incidence, mortality has decreased or stabilized in many countries

Research reported at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA, shows that the incidence of prostate cancer and associated mortality has generally declined or remained steady in most of the countries with available data.

08-04-2019 | Oncology | News | Article

SPARTAN: Apalutamide benefit seen for luminal, basal nonmetastatic CRPC

Supplementing androgen deprivation therapy with apalutamide improves metastasis-free survival in patients with the luminal and basal subtypes of nonmetastatic castration-resistant prostate cancer, indicates an analysis of the randomized SPARTAN trial.

08-04-2019 | Oncology | News | Article

FDA approves point-of-care PSA test

Click through to read the details

31-03-2019 | Oncology | News | Article

Abiraterone may raise mortality risk in men with prostate cancer, CVD

Among men initiating abiraterone acetate for advanced prostate cancer, the mortality risk may be higher for those with versus without pre-existing cardiovascular disease, suggests a real-world study presented at the AACR Annual Meeting 2019 in Atlanta, Georgia, USA.

27-03-2019 | Prostate cancer | News | Article

Carbon ion radiotherapy may reduce future tumor risk after prostate cancer

Patients who receive carbon ion radiotherapy for localized prostate cancer have a significantly lower risk for subsequent primary cancers than those treated with photon radiotherapy or surgery, retrospective study data suggest.

Image Credits